Themis Medicare Ltd.
Snapshot View

View in App

Prices View details >>

1110.75 -32.45 ▼-2.8%

28 March 2023, 04:01:00 PM
Volume: 608

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.themismedicare.com
Market Cap 1,018.29 Cr.
Enterprise Value(EV) 1,075.45 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 63.51 Trailing Twelve Months Ending 2022-12
Price-Earning Ratio (PE) 17.49 Trailing Twelve Months Ending 2022-12
Industry PE 32.00 Trailing Twelve Months Ending 2022-12
Book Value / Share 358.56 Trailing Twelve Months Ending 2022-12
Price to Book Value 3.10 Calculated using Price: 1,110.75
Dividend Yield 0.45 Period Ending 2022-03
No. of Shares Subscribed 0.92 Cr. 9,202,770 Shares
FaceValue 10
Company Profile
Themis Medicare (TML) incorporated in 1969, is engaged in manufacturing of Active Pharmaceutical Ingredients (APIs) and Formulations. Erstwhile known as Themis Chemical the company is promoted by Mr. Shantibhai D. Patel. It is joint venture with Gedeon Richter, Hungary.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
-2.84%
1 Week
-5.11%
1 Month
-7.45%
3 Month
-16.88%
6 Month
+10.49%
1 Year
+15.56%
2 Year
+290.42%
5 Year
+99.74%
10 Year
+2009.69%

Ratios View Details >>

9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 5.00 9.40 22.85 13.16 5.42 -8.00 9.34 13.09 24.35
Return on Capital Employed (%) 9.53 9.45 14.69 12.92 8.52 -1.25 11.81 15.21 27.68
Return on Assets (%) 0.97 1.94 5.52 5.29 2.95 -4.29 4.86 7.32 15.14

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 57 59 74 152 169 158 183 219 287 318
Non Curr. Liab. 90 82 71 8 7 3 8 24 31 29
Curr. Liab. 137 136 130 124 125 147 155 128 124 121
Minority Int. 0 0
Equity & Liab. 284 277 275 284 301 307 345 371 442 467
Non Curr. Assets 149 143 142 160 157 158 165 186 214 229
Curr. Assets 134 133 133 124 143 150 180 185 228 238
Misc. Exp. not W/O
Total Assets 284 277 275 284 301 307 345 371 442 467

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-12 Rs. Cr. TTM
Net Sales 195 202 232 217 210 184 202 231 395 354
Other Income 5 13 3 3 3 3 3 4 7 10
Total Income 200 214 236 220 213 186 205 234 401 364
Total Expenditure -171 -184 -194 -184 -185 -181 -166 -181 -299 -283
PBIDT 29 31 41 36 28 5 39 53 102 82
Interest -16 -15 -12 -12 -12 -12 -13 -13 -9 -9
Depreciation -9 -11 -12 -7 -7 -8 -8 -9 -9 -10
Taxation -1 1 -2 -2 0 2 -2 -6 -22 -18
Exceptional Items
PAT 3 5 15 15 9 -13 16 26 62 45
Minority Interest 0 0
Share Associate 1 1 1 3 2 9 9 11 14
Other Related Items
Consolidated Net Profit 3 6 16 16 11 -11 25 36 73 58
Adjusted EPS 3 7 19 18 12 -12 27 39 79 64

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 4 8 19 26 -2 8 11 0 57 34
Cash Fr. Inv. -5 -7 -6 -7 -4 0 -4 -5 -16 -16
Cash Fr. Finan. 29 2 -18 -13 5 -9 -10 7 -26 -18
Net Change 29 4 -5 5 0 -1 -3 2 16 1
Cash & Cash Eqvt -38 -35 -40 -34 6 4 2 3 19 20

Shareholding Pattern View Details >>

9 Qtrs 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 67.26 67.26 67.22 67.18 67.18 67.18 67.18 67.18 67.18
Public 32.74 32.74 32.78 32.82 32.82 32.82 32.82 32.82 32.82
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 23.51 23.51 23.51 23.51 23.51 23.51

Announcements View Details >>

Mon, 27 Mar 2023
Closure of Trading Window
We would like to inform you that as per the Companys minimum Standards Code of Conduct to regulate monitor and report trading by its Employees and other Connected Persons under SEBI (Prohibition of Insider Trading) Regulations 2015 (as amended) (PIT Regulations) and pursuant to BSE Circular Ref No: LIST/COMP /01/2019-20 dated 2nd April 2019 and NSE Circular Ref No. NSE/CML/2019/11 on the provisions of Clause 4 of the Schedule B of the PIT regulations the Trading Window for dealing in the Securities of the Company shall remain closed on and from 1st April 2023 and will re-open after completion of 48 hours from the declaration of financial results for the quarter and year ended 31st March 2023 by the Board of Directors of the Company.This is for your information and record.
Fri, 17 Feb 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (the Listing Regulations) read with part A of Schedule III of the Listing Regulations we wish to inform that the management of the Company did a one on one physical meeting with Analysts/Investors on Thursday 16th February 2023; the details of the same are given below:Sr. no. Name Venue1 Nuvama Wealth Management Themis OfficePursuant to regulation 46(2) of the Listing Regulations aforesaid information shall be disclosed on the website of the company viz. www.themismedicare.comThis is for your information and record.
Fri, 17 Feb 2023
Announcement under Regulation 30 (LODR)-Press Release / Media Release
In terms of Regulation 30 of the SEBI (LODR) Regulations 2015 we are enclosing herewith a copy of the press release titled - Themis Medicare announces DCGI approval of Remifentanil Hydrochloride 1mg/2mg for injection for import and marketing.Kindly take this on record.

Technical Scans View Details >>

Tue, 28 Mar 2023
High Delivery Percentage High Delivery Percentage
Close Crossing Last Week Low Close Crossing Last Week Low
Closing Below Previous Low Closing Below Previous Low
Close Below Last Week Low Close Below Last Week Low
Close Below Last Month Low Close Below Last Month Low

Related Stocks View Details >>

  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 236,142.55 983.20 -0.1%
Dr. Reddy's Laboratories Ltd. 75,408.82 4,534.70 +1.1%
Divi's Laboratories Ltd. 74,473.23 2,805.35 -0.8%
Cipla Ltd. 71,800.08 889.55 +0.0%
Apollo Hospitals Enterprise Ltd. 62,246.53 4,322.00 +0.0%
Torrent Pharmaceuticals Ltd. 52,239.05 1,539.00 +0.3%
Zydus Lifesciences Ltd. 49,031.17 484.40 +0.4%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 56.01 983.20 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 20.72 4,534.70 +1.1%
Divi's Laboratories Ltd. Consolidated 2022-12 31.07 2,805.35 -0.8%
Cipla Ltd. Consolidated 2022-12 27.21 889.55 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-12 81.27 4,322.00 +0.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 62.68 1,539.00 +0.3%
Zydus Lifesciences Ltd. Consolidated 2022-12 23.79 484.40 +0.4%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 4.27 983.20 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.43 4,534.70 +1.1%
Divi's Laboratories Ltd. Consolidated 2022-12 5.99 2,805.35 -0.8%
Cipla Ltd. Consolidated 2022-12 3.16 889.55 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-12 10.07 4,322.00 +0.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.17 1,539.00 +0.3%
Zydus Lifesciences Ltd. Consolidated 2022-12 2.84 484.40 +0.4%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 983.20 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,534.70 +1.1%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 2,805.35 -0.8%
Cipla Ltd. Consolidated 2022-03 0.04 889.55 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,322.00 +0.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,539.00 +0.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 0.25 484.40 +0.4%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 983.20 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,534.70 +1.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,805.35 -0.8%
Cipla Ltd. Consolidated 2022-03 13.10 889.55 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,322.00 +0.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,539.00 +0.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 484.40 +0.4%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 983.20 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,534.70 +1.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,805.35 -0.8%
Cipla Ltd. Consolidated 2022-03 13.10 889.55 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,322.00 +0.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,539.00 +0.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 484.40 +0.4%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 983.20 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,534.70 +1.1%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 2,805.35 -0.8%
Cipla Ltd. Consolidated 2022-03 21,763.34 889.55 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,322.00 +0.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,539.00 +0.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 15,265.20 484.40 +0.4%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 983.20 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,182.50 4,534.70 +1.1%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 2,805.35 -0.8%
Cipla Ltd. Consolidated 2022-03 2,559.47 889.55 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,322.00 +0.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,539.00 +0.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 2,326.40 484.40 +0.4%

FAQ's On Themis Medicare Ltd.

What is Themis Medicare share price?
Can I buy Themis Medicare shares now?
What is the Dividend Yield of Themis Medicare?
What is the Market Cap of Themis Medicare?
What are the key metrics to analyse Themis Medicare?
What is the 52 Week High and Low of Themis Medicare?
What is the trend of Themis Medicare share price?